Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette-Guerin (BCG) for infants of HIV infected mothers: A phase 2 randomized controlled trial.

Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette-Guerin (BCG) for infants of HIV infected mothers: A phase 2 randomized controlled trial.

<h4>Background</h4> <p>Vaccination of HIV-infected infants with bacille Calmette-Guérin (BCG) is contraindicated. HIV-exposed newborns need a new tuberculosis (TB) vaccination strategy that protects against TB early in life; and avoids the potential risk of BCG disease until after...

Full description

Bibliographic Details
Main Authors: Nemes, E, Hesseling, A, Tameris, M, Mauff, K, Downing, K, Mulenga, H, Rose, P, van der Zalm, M, Mbaba, S, Van As, D, Hanekom, W, Walzl, G, Scriba, T, McShane, H, Hatherill, M
Format: Journal article
Language:English
Published: Oxford University Press 2017

Similar Items

Similar Items